Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer

Overexpression of the HER2/Neu (ErbB2) proto-oncogene is associated with breast cancer progression and poor patient prognosis. Herceptin (trastuzumab) is a humanized IgG1 against the ectodomain of the HER2 receptor. In combination with chemotherapy, it induces regression of HER2-overexpressing metas...

Descripción completa

Detalles Bibliográficos
Autor principal: Arteaga, Carlos L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC154152/
https://www.ncbi.nlm.nih.gov/pubmed/12631388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC154152/
https://www.ncbi.nlm.nih.gov/pubmed/12631388

Ejemplares similares